NR3C1 and Cowden disease: Finally, combination therapy could be considered a valuable alternative in patients unresponsive to a single drug treatment, even if further larger studies are needed to assess the efficacy and safety of a polypharmacotherapy for CD treatment, especially for unexplored combinations, such as GR antagonists and pituitary-directed agents.